tradipitant
Small molecule
Also known as VLY-686
Evidence outlook
Approved: NEREUS is indicated for the prevention of vomiting induced by motion in adults. (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
Also approved (1)
- NEREUS is indicated for the prevention of vomiting induced by motion in adults.
Result from the sponsor's press release; no peer-reviewed publication of this trial was found.
Company guidance: data expected by end of 2026 (Vanda Pharmaceuticals, 5 Aug 2026). “Results for three Phase III clinical trials expected by end of 2026: NEREUS™ (tradipitant) in vomiting in GLP-1 ,” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04028492 NCT04028492 · Gastroparesis The study was randomized and quadruple-blinded with placebo control; the primary efficacy comparison included 102 tradipitant-treated and 99 placebo-treated participants. The clinical symptom endpoint was missed, with no statistically significant difference in nausea-severity improvement between groups (p=0.7411), so the findings provide well-controlled but inconclusive evidence of benefit. Registry: NCT04028492 | 3 | Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population (12 weeks) 2025-02-21 | Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population (12 weeks): Tradipitant -1.55 score on a scale (95% CI -1.82 to -1.29) | Placebo -1.49 score on a scale (95% CI -1.76 to -1.23) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow tradipitant to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent